Naslov
Terapija inhibitorima protonske pumpe uzrokuje porast koncentracije kromogranina A
(Proton pump inhibitor therapy causes increased chromogranine A concentration)

Autori
Šahinović, Ines ; Borzan, Vladimir ; Fijačko, Mirjana ; Šerić, Vatroslav

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Biochemia Medica 2018 ; 28(Suppl 1):S1-S223 / - Zagreb, 2018, S96-S97

Skup
9. kongres hrvatskog društva za medicinsku biokemiju i laboratorijsku medicinu (HDMBLM)

Mjesto i datum
Zagreb, Hrvatska, 09.05.2018. - 12.05.2018

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
Kromogranin A, inhibitori protonske pumpe, neuroendokrini tumori
(Chromogranin A, proton pump inhibitors, neuroendocrine tumor)

Sažetak
INTRODUCTION: Chromogranine A is considered a pan- neuroendocrine tumor marker. It has been used widely as a sensitive marker in the diagnosis and follow-up of neuroendocrine tumors (NETs). Proton pump inhibitors (PPI) significantly increase gastrin secretion, cause hyperproliferation of chromaffin-like cells of the stomach and change chromogranine A release. The aim of the study was to determine the effect of PPI therapy and its discontinuation on chromogranine A level in serum. SUBJECTS AND METHODS: Fasting serum chromogranine A was determined in twenty patients diagnosed with gastroesophageal reflux disease (GERD) and chronic gastritis treated with PPI. 3-6 weeks after PPI therapy discontinuation serum chromogranine A measurement was repeated. Chromogranine A was also determined in serum of 30 healthy subjects. Results of chromogranine A were compared to NET group of patients (N =75), whose values were generated from laboratory database. The results are presented as median and interquartile range. Differences between groups were tested using the Wilcoxon paired test and Mann-Whitney test. Significance was assumed at P≤0, 05. RESULTS: Median value of chromogranine A decreased from 162 µg/L (143 - 196 µg/L) during PPI treatment to 61, 5 µg/L (32 - 87 µg/L) after PPI discontinuation (P<0, 0001). Treatment with PPI resulted in a significant increase (25 – 90%) in chromogranine A serum concentration. Chromogranine A values differed significantly between group of patients on PPI therapy and healthy subjects (P<0, 0001), but also between group of patients on PPI therapy and NET group of patients (P<0, 0001). CONCLUSION: PPI treatment results in a significant increase of chromogranine A concentration in serum. Considering the widespread administration of PPIs, this effect needs to be considered when interpreating results of chromogranine A measurements to avoid false positive data and prevent unnecessary expensive diagnostic work-up in screening for NETs.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)

POVEZANOST RADA